Navigation Links
Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
Date:7/22/2008

t guides the surgeon's moves during the laser treatment and a sterile sheath for working in the operating room. EkkyLite(TM) activates and stimulates the skin regeneration process resulting in faster healing, while preventing, reducing and sometimes completely erasing surgical scars.

The therapeutic, aesthetic and practical benefits provided by EkkyLite(TM) makes it the first laser technology accessible to all surgeons: not only plastic surgeons but also specialists experiencing scarring issues such as dermatologists, obstetricians, trauma specialists...

Currently in clinical phase, the commercialization of the Ekkylite(TM) system is forecasted for 2008 in France and for 2009 successively in Europe and the United States. Based in Meyreuil, France, Ekkyo has 8 staff members as of December 2007.

More on http://www.ekkyo.com

*Alexandre C. Capon et al. LSM-08-0066 (20657)

Lasers in Surgery and Medicine publishes the highest quality research and clinical manuscripts in areas relating to the use of lasers in medicine and biology. The journal publishes basic and clinical studies on the therapeutic and diagnostic use of lasers in all the surgical and medical specialties.


'/>"/>
SOURCE EKKYO
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
2. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
3. Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimers Drug After Flurizans Discontinuation
4. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
5. Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments
6. Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
9. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
10. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
11. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 Investor-Edge has initiated ... VVUS ), Horizon Pharma PLC (NASDAQ: HZNP ), ... (NYSE: JNJ ), and Theravance Inc. (NASDAQ: ... be accessed at: http://investor-edge.com/register . On Tuesday, ... 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to ...
(Date:11/26/2014)... A hernia is condition in which ... the wall of a weak muscle area. Obesity, poor nutrition, ... of the causes of hernias. There are several types of ... inguinal hernia is when part of the abdominal tissue/organ protrudes ... the area of the umbilicus. A hiatal hernia is when ...
(Date:11/26/2014)... Calif. , Nov. 26, 2014  Aridis ... to produce novel therapies for infectious diseases, announced ... M.D., an internationally recognized key opinion leader in ... Company,s scientific advisory board. Founder and ... stated, "We believe Dr. Opal,s extensive experience investigating ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... a leading developer of innovative catheters and stents for ... closing of a $17M Round D financing.  The financing ... based EDB Investments (,EDBI,) with strong support from current ... are delighted to have Bio*One join our group of ...
... Arable Corporation ( www.arablecorp.com ) has announced the launch ... the clinical trial industry.  Whereas traditional CTMS systems have ... CTMS and EDC capabilities without the traditionally high start-up ... or CROs to manage the planning and implementation of ...
Cached Medicine Technology:TriReme Medical Announces $17 Million Series D Financing 2Arable Corporation Announces New Technology for Clinical Trial Industry 2
(Date:11/27/2014)... November 27, 2014 Now that Thanksgiving ... has officially launched, Emassagechair.com has announced its ... Discount Event. , Negotiating on behalf of their ... massage chair brands, Emassagechair.com has generated significant buzz in ... and biggest discounts yet. , Shoppers are excited for ...
(Date:11/27/2014)... 2014 VogueQueen.com is making every effort ... across the world. As the premier online supplier of ... proud to release a huge selection of sexy prom ... it is also providing many beautiful styles in its ... at discounted prices. , “VogueQueen.com hopes to provide ...
(Date:11/27/2014)... Viejo, California (PRWEB) November 27, 2014 Developers ... announced a new plugin entitled ProPip, taking FCPX to the ... in picture effect with a few clicks of a mouse,” ... a time saver that our users will appreciate.” , With ... full customization leaving the possibilities truly endless. ProPip is great ...
(Date:11/27/2014)... 27, 2014 HealthPostures, a ... equipment , has announced that it has entered ... Environments. The partnership will put HealthPostures' products into ... , In addition to having its products sold ... promotes HealthPostures' products with the business decision makers ...
(Date:11/27/2014)... November 27, 2014 At The Little ... So it came as no surprise when a recent ... child’s academic success. The Journal of Pediatrics ... and motor tasks during the school years may be ... academic development.” The study monitored two groups of children; ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... Care at the 15th SPSSCS Annual Meeting , ... New York, NY ... Specialists (SPSSCS) celebrates its 15th Annual Meeting - Play the Winning Hand: ... Vegas, NV. The meeting offers educational seminars for nurses, aestheticians ...
... Aeroportuario del Sureste, S.A.B. de C.V. (NYSE: ASR ... in Mexico and operator of Cancun Airport and eight others ... 26, 2009 the Mexican Secretary of Health confirmed the presence ... 28, 2009 the World Health Organization (the "WHO") acknowledged the ...
... Executive Chairman & CEO Douglas MacLellan offers expert insight ... April 29 AMDL Inc. ... major operations in China, announced today its Executive Chairman ... featured in The Wall Street Transcript - ...
... 23 June 2009, the Prostate Cancer Translational Research ... the Beurs van Berlage in Amsterdam (NL). Translational ... or population studies into clinical applications to reduce ... Association of Urology (EAU) provides an excellent forum ...
... Sales & Marketing Data In One Screen To ... Custom Metrics EWING, N.J., April 29 Archi-Tech ... reporting solutions, today announced the availability of managed ... portal for pharmaceutical sales reporting. Using InView, managed ...
... New analyses of data from the 16-Year ... by Bayer HealthCare Pharmaceuticals, were presented at the ... The study results showed that early and ... multiple sclerosis (MS) were more likely to avoid ...
Cached Medicine News:Health News:Play the Winning Hand - Watching Your Fortunes Grow in Skin Care 2Health News:Play the Winning Hand - Watching Your Fortunes Grow in Skin Care 3Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 2Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 3Health News:EAU Research Foundation organizes meeting in Amsterdam highlighting translational research results 2Health News:Archi-Tech InView Now Supports Managed Care Data, Offering an Interactive Dashboard for On-Demand Sales Planning and Reporting 2Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 2Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 3Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 4